Beyond ALK fusion positivity: structural complexity as a prognostic indicator in first-line ALK-TKI therapy

Area of Science:

• Oncology
• Genomics
• Thoracic Surgery

Background:

• Tyrosine kinase inhibitors (TKIs) have improved outcomes for anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC).
• Emerging ALK rearrangement subtypes require further investigation regarding TKI efficacy.
• Genomic sequencing advancements facilitate detailed analysis of ALK rearrangements.

Purpose of the Study:

• To investigate the therapeutic outcomes of first-line ALK-TKIs in NSCLC patients based on ALK rearrangement subtypes.
• To identify prognostic factors associated with different ALK rearrangement patterns in NSCLC.

Main Methods:

• Retrospective analysis of 118 NSCLC patients with ALK rearrangements identified by next-generation sequencing (NGS).
• Assessment of therapeutic outcomes in 89 patients receiving first-line ALK-TKIs, stratified by ALK rearrangement subtypes.
• Comparison of progression-free survival (PFS) and overall survival (OS) between patients with nonreciprocal/reciprocal ALK translocations and solitary 3'-ALK fusions.

Main Results:

• Nonreciprocal/reciprocal ALK translocations were identified in 30.5% of patients, solitary EML4-ALK fusions in 61.9%, and solitary non-EML4-ALK fusions in 7.6%.
• Patients with nonreciprocal/reciprocal translocations (32.6%) had significantly shorter median PFS (15.6 months) compared to those with solitary 3'-ALK fusions (67.4%, 31.1 months).
• No significant difference in median overall survival was observed between the groups; TP53 mutations were common co-occurring alterations without significant frequency differences.

Conclusions:

• Nonreciprocal/reciprocal ALK translocations are an independent adverse prognostic factor in ALK-positive NSCLC.
• The poorer prognosis associated with these translocations is not directly linked to TP53 co-mutations.
• These findings underscore the importance of characterizing ALK rearrangement subtypes for personalized NSCLC treatment strategies.